Study Summary
This is a Phase 1/1b, open-label, dose-escalation study to evaluate the safety and the efficacy of anti-CD19 chimeric antigen receptor (CAR) (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).
Want to learn more about this trial?
Request More InfoInterventions
TBI-2001BIOLOGICAL
Phase-I portion:
cohort 1: 3×10\^5 cells/kg, cohort 2: 1×10\^6 cells/kg, cohort 3: 3×10\^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion.
CyclophosphamideDRUG
IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
FludarabineDRUG
IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Princess Margaret Cancer Centre | Toronto | Ontario | Canada |